Publication Name	World Journal of Gastroenterology
Manuscript ID	32686
Country	Japan

Received	2017-01-19 10:14
Peer-Review Started	2017-01-19 14:09
To Make the First Decision	2017-02-23 10:25
Return for Revision	2017-02-27 15:28
Revised	2017-03-10 12:35
Second Decision	2017-04-14 17:32
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-04-21 15:17
Articles in Press	2017-04-21 15:17
Publication Fee Transferred	2017-05-10 13:44
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-07-31 07:17
Publish the Manuscript Online	2017-08-07 09:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Masayuki Miyazaki, Masayoshi Yada, Kosuke Tanaka, Takeshi Senjyu, Takeshi Goya, Kenta Motomura, Motoyuki Kohjima, Masaki Kato, Akihide Masumoto and Kazuhiro Kotoh
Funding Agency and Grant Number
Corresponding Author	Masayuki Miyazaki, MD, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio, Iizuka 820-8505, Japan. mmasayuk@med.kyushu-u.ac.jp
Key Words	Ascites; Tolvaptan; Furosemide; Cirrhosis; Hepatocellular carcinoma
Core Tip	Efficacy of tolvaptan (TLV) for hepatic ascites has been confirmed but some patients are resistant to the drug. We investigate influencing factors of the efficacy of TLV. As a result, coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV. In stratified analysis, high doses of furosemide decreased the efficacy of TLV in patients with HCC, and increased efficacy in those without HCC. This study suggests that development of ascites may differ between patients with liver failure and those with HCC progression. A sufficient preceding dose of furosemide decreases diuretic effect of TLV.
Publish Date	2017-08-07 09:17
Citation	Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5379-5385
URL	http://www.wjgnet.com/1007-9327/full/v23/i29/5379.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i29.5379

Full Article (PDF)	WJG-23-5379.pdf
Full Article (Word)	WJG-23-5379.doc
Manuscript File	32686-Review.doc
Answering Reviewers	32686-Answering reviewers.pdf
Audio Core Tip	32686-Audio core tip.mp3
Biostatistics Review Certificate	32686-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	32686-Conflict-of-interest statement.pdf
Copyright License Agreement	32686-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	32686-Infromed consent statement.pdf
Institutional Review Board Approval Form or Document	32686-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	32686-Language certificate.pdf
Peer-review Report	32686-Peer-review(s).pdf
Scientific Misconduct Check	32686-Scientific misconduct check.pdf
Scientific Editor Work List	32686-Scientific editor work list.pdf